GCO reports a narrower-than-expected loss per share and sales beat in second-quarter fiscal 2025. E-commerce comps rose 8%.
Vous n'êtes pas connecté
Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.
GCO reports a narrower-than-expected loss per share and sales beat in second-quarter fiscal 2025. E-commerce comps rose 8%.
GCO reports a narrower-than-expected loss per share and sales beat in second-quarter fiscal 2025. E-commerce comps rose 8%.
Academy Sports' second-quarter fiscal 2024 results reflect soft demand trends due to macroeconomic uncertainties.
CAL posts sales and earnings miss in the second quarter of fiscal 2024. The Famous Footwear segment witnesses a higher market share in the Kids...
CAL posts sales and earnings miss in the second quarter of fiscal 2024. The Famous Footwear segment witnesses a higher market share in the Kids...
Lovesac's second-quarter fiscal 2025 results benefit from new showrooms and product innovation.
VIRC's second-quarter fiscal 2024 results benefit from higher factory output and improved operating efficiencies, along with a significant...
VIRC's second-quarter fiscal 2024 results benefit from higher factory output and improved operating efficiencies, along with a significant...
ZUMZ's fiscal Q2 results are aided by a strong North America business, reflecting comps growth in June and July, particularly driven by the onset of...
NIO reports better-than-expected second-quarter results and expects third-quarter 2024 vehicle deliveries in the range of 61,000-63,000 units.